Scale of Equipment Supply: GE HealthCare will supply over 300 CT scanners to public hospitals across all 38 provinces in Indonesia under the SIHREN program, aiming to deliver equitable, high-quality healthcare to more than 280 million Indonesians.
Compliance with International Tender: The procurement of CT scanners was conducted through a fully competitive international tender process governed by World Bank regulations, marking one of the largest healthcare infrastructure investments in Indonesia's history.
Enhanced Health Management: This initiative will modernize the national referral system with a focus on non-communicable disease management and maternal health, expected to significantly improve health outcomes in Indonesia, particularly in early detection and timely treatment of critical conditions like cancer, stroke, and heart disease.
Local Manufacturing Capability: The newly inaugurated production facility in Bogor by GE HealthCare will strengthen local supply chain resilience and develop skilled healthcare professionals through technology transfer and training, further promoting sustainable development of Indonesia's healthcare system.
GEHC
$82.25+Infinity%1D
Analyst Views on GEHC
Wall Street analysts forecast GEHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GEHC is 88.18 USD with a low forecast of 80.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast GEHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GEHC is 88.18 USD with a low forecast of 80.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 84.450
Low
80.00
Averages
88.18
High
95.00
Current: 84.450
Low
80.00
Averages
88.18
High
95.00
Jefferies
Jay Saccaro
maintain
$95 -> $105
2025-12-11
Reason
Jefferies
Jay Saccaro
Price Target
$95 -> $105
2025-12-11
maintain
Reason
Jefferies raised the firm's price target on GE HealthCare to $105 from $95 and keeps a Buy rating on the shares after having hosted a call with CFO Jay Saccaro and other executives. The firm, which was "encouraged" by GE HealthCare's Q3 performance and leading indicators, sees stable to improving fundamentals and "a strong catalyst path" with consensus appearing to model very little contribution from Flyrcado or Vizamyl/Cerianna, the analyst tells investors.
Citi
Neutral
maintain
$83 -> $88
2025-12-11
Reason
Citi
Price Target
$83 -> $88
2025-12-11
maintain
Neutral
Reason
Citi raised the firm's price target on GE HealthCare to $88 from $83 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is "bouncing off its lows," and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index "remains undervalued and underappreciated." The firm expects a rebound next year due to company catalysts and sector rotation.
Wells Fargo
Larry Biegelsen
Overweight
maintain
$89 -> $87
2025-10-30
Reason
Wells Fargo
Larry Biegelsen
Price Target
$89 -> $87
2025-10-30
maintain
Overweight
Reason
Wells Fargo analyst Larry Biegelsen lowered the firm's price target on GE HealthCare to $87 from $89 and keeps an Overweight rating on the shares. The firm notes the company delivered a beat on the top line and EPS of $1.07 was ahead of both consensus and Wells Fargo's estimates. EBIT margins were down 150bps year-over-year, but above the firm's estimates. GE HealthCa raised the lower end of 2025 EPS guidance, but Flyrcado to be less than $30M in 2025 sales.
Morgan Stanley
Patrick Wood
Equal Weight
maintain
$74 -> $80
2025-10-29
Reason
Morgan Stanley
Patrick Wood
Price Target
$74 -> $80
2025-10-29
maintain
Equal Weight
Reason
Morgan Stanley analyst Patrick Wood raised the firm's price target on GE HealthCare to $80 from $74 and keeps an Equal Weight rating on the shares. The firm said it updated its model for Q3 earnings, which were slightly above expectations. Demand is looking solid for GE HealthCare, with solid order backlog and peer results, and the firm's hospital CapEx survey suggests a healthy environment, the analyst tells investors in a research note. The analyst added that it equally believes mid-term margin targets are sensible and sees upside risk long-term from photon counting.
About GEHC
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
